Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1999-3-10
|
| pubmed:abstractText |
The HIV-inhibitory activity in extracts of Allanblackia stuhlmannii was tracked, via bioassay-guided fractionation, to a new member of the camboginol/guttiferone class of prenylated benzophenones, guttiferone F (1). The structure was solved by extensive NMR analyses and by acid-catalyzed conversion to 30-epi-cambogin (4). This is the first report of this compound type in the genus Allanblackia.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0163-3864
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
62
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
130-2
|
| pubmed:dateRevised |
2001-11-13
|
| pubmed:meshHeading | |
| pubmed:year |
1999
|
| pubmed:articleTitle |
Guttiferone F, the first prenylated benzophenone from Allanblackia stuhlmannii.
|
| pubmed:affiliation |
Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute-Frederick Cancer Research and Development Center, Building 1052, Room 121, Frederick, MD 21702-1201, USA.
|
| pubmed:publicationType |
Journal Article
|